{"id":"https://openalex.org/W4379282910","doi":"https://doi.org/10.1200/jco.2023.41.16_suppl.3089","title":"Sudocetaxel zendusortide (TH1902), a novel sortilin-receptor (SORT1)-targeting peptide-drug-conjugate (PDC) in patients (pts) with advanced solid tumors: Results from part 1 (dose-escalation) of a phase 1, open-label study.","display_name":"Sudocetaxel zendusortide (TH1902), a novel sortilin-receptor (SORT1)-targeting peptide-drug-conjugate (PDC) in patients (pts) with advanced solid tumors: Results from part 1 (dose-escalation) of a phase 1, open-label study.","publication_year":2023,"publication_date":"2023-06-01","ids":{"openalex":"https://openalex.org/W4379282910","doi":"https://doi.org/10.1200/jco.2023.41.16_suppl.3089"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2023.41.16_suppl.3089","doi":"https://doi.org/10.1200/jco.2023.41.16_suppl.3089","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1200/jco.2023.41.16_suppl.3089","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5076426660","display_name":"Funda Meric\u2010Bernstam","orcid":"https://orcid.org/0000-0001-6816-6072","observed_orcids":["https://orcid.org/0000-0001-6816-6072"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Funda Meric-Bernstam","raw_affiliation_strings":["Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109431602","display_name":"Satish Kumar Shah","orcid":"https://orcid.org/0000-0003-2716-4091","observed_orcids":["https://orcid.org/0000-0003-2716-4091"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Satish Shah","raw_affiliation_strings":["Gettysburg Cancer Center, Gettysburg, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gettysburg Cancer Center, Gettysburg, PA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101836399","display_name":"Manish R. Sharma","orcid":"https://orcid.org/0000-0002-6711-1552","observed_orcids":["https://orcid.org/0000-0002-6711-1552"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Manish Sharma","raw_affiliation_strings":["START Midwest, Grand Rapids, MI"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"START Midwest, Grand Rapids, MI","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065599773","display_name":"Annick Metcalfe","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210165640","display_name":"Theratechnologies (Canada)","ror":"https://ror.org/05d3bn235","country_code":"CA","type":"company","lineage":["https://openalex.org/I4210165640"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Annick Metcalfe","raw_affiliation_strings":["Theratechnologies Inc., Montr\u00e9al, QC, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Theratechnologies Inc., Montr\u00e9al, QC, Canada","institution_ids":["https://openalex.org/I4210165640"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034678888","display_name":"Guylaine Roy","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210165640","display_name":"Theratechnologies (Canada)","ror":"https://ror.org/05d3bn235","country_code":"CA","type":"company","lineage":["https://openalex.org/I4210165640"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Guylaine Roy","raw_affiliation_strings":["Theratechnologies Inc., Montreal, QC, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Theratechnologies Inc., Montreal, QC, Canada","institution_ids":["https://openalex.org/I4210165640"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002185895","display_name":"Lynn Marie Douglas","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210165640","display_name":"Theratechnologies (Canada)","ror":"https://ror.org/05d3bn235","country_code":"CA","type":"company","lineage":["https://openalex.org/I4210165640"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Lynn Marie Douglas","raw_affiliation_strings":["Theratechnologies, Montreal, QC, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Theratechnologies, Montreal, QC, Canada","institution_ids":["https://openalex.org/I4210165640"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070686853","display_name":"Christian Marsolais","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210165640","display_name":"Theratechnologies (Canada)","ror":"https://ror.org/05d3bn235","country_code":"CA","type":"company","lineage":["https://openalex.org/I4210165640"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Christian Marsolais","raw_affiliation_strings":["Theratechnologies, Montreal, QC, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Theratechnologies, Montreal, QC, Canada","institution_ids":["https://openalex.org/I4210165640"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5039736511","display_name":"Ira Seth Winer","orcid":"https://orcid.org/0000-0001-6056-8296","observed_orcids":["https://orcid.org/0000-0001-6056-8296"]},"institutions":[{"id":"https://openalex.org/I4210090317","display_name":"The Barbara Ann Karmanos Cancer Institute","ror":"https://ror.org/00ee40h97","country_code":"US","type":"facility","lineage":["https://openalex.org/I2800590384","https://openalex.org/I4210090317"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ira Seth Winer","raw_affiliation_strings":["Barbara Ann Karmanos Cancer Institute, Detroit, MI"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Barbara Ann Karmanos Cancer Institute, Detroit, MI","institution_ids":["https://openalex.org/I4210090317"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":5,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"41","issue":"16_suppl","first_page":"3089","last_page":"3089"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10063","display_name":"Nanoparticle-Based Drug Delivery","score":0.6801999807357788,"subfield":{"id":"https://openalex.org/subfields/2502","display_name":"Biomaterials"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},"topics":[{"id":"https://openalex.org/T10063","display_name":"Nanoparticle-Based Drug Delivery","score":0.6801999807357788,"subfield":{"id":"https://openalex.org/subfields/2502","display_name":"Biomaterials"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10911","display_name":"Chemical Synthesis and Analysis","score":0.06300000101327896,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10725","display_name":"RNA Interference and Gene Delivery","score":0.04430000111460686,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/sort1","display_name":"SORT1","score":0.746999979019165},{"id":"https://openalex.org/keywords/peptide-drug-conjugates","display_name":"peptide-drug conjugates","score":0.9729999899864197},{"id":"https://openalex.org/keywords/docetaxel","display_name":"docetaxel","score":0.9340000152587891},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.9020000100135803},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.7419999837875366},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.953000009059906},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.8259999752044678},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9779999852180481},{"id":"https://openalex.org/keywords/ovarian-cancer","display_name":"ovarian cancer","score":0.5669999718666077},{"id":"https://openalex.org/keywords/breast-cancer","display_name":"breast cancer","score":0.609000027179718},{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.8410000205039978},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.8450000286102295},{"id":"https://openalex.org/keywords/prostate-cancer","display_name":"prostate cancer","score":0.46000000834465027},{"id":"https://openalex.org/keywords/endometrial-cancer","display_name":"endometrial cancer","score":0.9160000085830688},{"id":"https://openalex.org/keywords/cervical-cancer","display_name":"cervical cancer","score":0.8460000157356262}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8216079473495483},{"id":"https://openalex.org/C2781190966","wikidata":"https://www.wikidata.org/wiki/Q420436","display_name":"Docetaxel","level":3,"score":0.8211648464202881},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.8177282810211182},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.5353612899780273},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5040451884269714},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4879600405693054},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.483367383480072},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.44558796286582947},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4228816628456116},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.35371747612953186}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2023.41.16_suppl.3089","doi":"https://doi.org/10.1200/jco.2023.41.16_suppl.3089","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1200/jco.2023.41.16_suppl.3089","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9391000270843506,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4400274087","https://openalex.org/W4410817483","https://openalex.org/W3182363921","https://openalex.org/W4362592856","https://openalex.org/W4224249674","https://openalex.org/W4282915372","https://openalex.org/W7167797621","https://openalex.org/W7162660495","https://openalex.org/W4401281265","https://openalex.org/W3182886812"],"abstract_inverted_index":{"3089":[0],"Background:":[1],"SORT1":[2,182,240,439],"is":[3,17,457],"expressed":[4],"in":[5,82,251,367,415,422,431],"a":[6,18,36,65,90,300,357],"variety":[7],"of":[8,25,28,52,64,80,100,104,117,124,152,165,188,198,203,227,230,244,276,289,359,364,391,455],"tumors":[9,133],"when":[10],"compared":[11],"to":[12,31,54,72,141,157,178,192,207,239,345],"most":[13],"healthy":[14],"tissue.":[15],"TH1902":[16,81,105,118,231,456],"first-in-class":[19],"PDC":[20],"targeting":[21],"SORT1,":[22],"that":[23,135],"consists":[24],"2":[26,219,338],"molecules":[27],"docetaxel":[29],"attached":[30],"the":[32,41,55,74,109,113,120,189,194,209,214,225,228,296,314,319,341,349,451],"TH19P01":[33],"peptide":[34,43],"via":[35],"cleavable":[37],"succinyl":[38],"linker.":[39],"Conjugating":[40],"short":[42],"with":[44,130,428],"various":[45],"anti-cancer":[46],"agents":[47],"allows":[48],"for":[49,108,181,217,299],"targeted":[50],"delivery":[51],"payloads":[53],"tumor.":[56],"Here":[57],"we":[58],"report":[59],"results":[60],"from":[61],"Part":[62,87,204,218,252,416],"1":[63,69,88,205,253,258,260,270,287,417,425],"FIH,":[66],"multicenter,":[67],"phase":[68],"study,":[70],"designed":[71],"explore":[73],"safety,":[75],"pharmacokinetics":[76],"(PK)":[77],"and":[78,119,154,170,196,213,232,235,254,269,292,336,384,397,434,438],"efficacy":[79],"advanced":[83,131],"solid":[84,132],"tumors.":[85],"Methods:":[86],"used":[89,107],"modified":[91],"rapid":[92],"intrapatient":[93],"dose":[94,99,212,216,288,322,342],"escalation":[95],"design.":[96],"A":[97],"starting":[98],"30":[101],"mg/m2":[102,306,321,352],"Q3W":[103,307],"was":[106,191,206,343,420],"study":[110,190,290],"based":[111],"on":[112,149],"available":[114],"pre-clinical":[115],"data":[116],"known":[121],"safety":[122,195,311],"profile":[123],"docetaxel.":[125],"Eligibility":[126],"criteria":[127],"included":[128,224,255],"pts":[129,248,283,355,414],"(all-comers)":[134],"have":[136,158],"relapsed":[137],"or":[138],"are":[139,442],"refractory":[140],"standard":[142],"anticancer":[143],"treatment.":[144],"Pts":[145,174,272],"had":[146,377],"no":[147],"limit":[148],"previous":[150],"lines":[151],"therapy,":[153],"were":[155,175,249,293,308,393],"required":[156,177],"measurable":[159],"disease":[160],"by":[161],"RECIST,":[162],"expected":[163],"survival":[164],"\u22653":[166],"months,":[167],"ECOG":[168],"0-1,":[169],"adequate":[171],"organ":[172],"function.":[173],"not":[176],"be":[179],"tested":[180],"at":[183,285,318,350],"entry.":[184],"The":[185,200],"primary":[186,201],"objective":[187,202],"characterize":[193],"tolerability":[197],"TH1902.":[199],"identify":[208],"maximum":[210],"tolerated":[211],"recommended":[215],"(dose":[220],"expansion).":[221],"Additional":[222],"objectives":[223],"examination":[226],"PK":[229,437],"free":[233],"docetaxel,":[234],"outcomes":[236],"as":[237],"related":[238],"expression.":[241],"Results:":[242],"As":[243],"April":[245],"2022,":[246],"18":[247],"enrolled":[250,317],"6":[256,315],"ovarian,":[257],"endometrial,":[259],"cervical,":[261],"3":[262,264,267,325,333,379,386],"prostate,":[263],"ER+/Her2+":[265],"BC,":[266],"melanoma":[268],"NSCLC.":[271],"received":[273,284,356],"an":[274],"average":[275],"8":[277],"prior":[278],"regimens":[279],"(range:":[280],"3-20).":[281],"All":[282],"least":[286],"drug":[291],"evaluated":[294],"after":[295],"1st":[297],"cycle":[298],"DLT.":[301],"Dose":[302],"levels":[303],"between":[304],"30-420":[305],"studied.":[309],"Following":[310],"observations":[312],"among":[313],"patients":[316],"420":[320],"level":[323],"(Gr":[324],"neuropathy":[326],"[n=2],":[327,331],"Gr":[328,332,337,373,378,385,395],"4":[329],"neutropenia":[330],"ocular":[334,399],"[n=1]":[335],"skin":[339],"toxicities),":[340],"reduced":[344],"300":[346,351],"mg/m2.":[347],"At":[348],"cohort,":[353],"seven":[354],"mean":[358],"2.9":[360],"cycles.":[361],"AEs":[362,390],"(regardless":[363],"relatedness)":[365],"occurred":[366],"all":[368,394],"7":[369],"(100%)":[370],"pts,":[371],"mostly":[372],"1-2.":[374],"One":[375],"pt":[376],"worsening":[380],"anemia":[381],"(probably":[382],"related)":[383],"abdominal":[387],"pain/fistula":[388],"(unrelated).":[389],"interest":[392],"1-2,":[396],"included:":[398],"(keratitis/dryness)=2":[400],"pts;":[401,404,406],"GI":[402],"(nausea/vomiting/diarrhea)=2":[403],"neuropathy=2":[405],"MSK":[407],"(arthralgia/myalgia/extremity":[408],"pain)=2":[409],"pts.":[410],"In":[411],"15":[412],"evaluable":[413],"clinical":[418],"benefit":[419],"observed":[421],"10":[423],"pts:":[424],"PR":[426],"(prostate":[427],"53%":[429],"decrease":[430],"target":[432],"lesion)":[433],"9":[435],"SD.":[436],"expression":[440],"analyses":[441],"ongoing.":[443],"Conclusions:":[444],"Although":[445],"biological":[446],"activity":[447],"has":[448],"been":[449],"observed,":[450],"optimal":[452],"dosing":[453],"regimen":[454],"currently":[458],"under":[459],"evaluation.":[460],"Clinical":[461],"trial":[462],"information:":[463],"NCT04706962":[464],".":[465]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":2}],"updated_date":"2026-10-02T10:15:12.560889","created_date":"2023-06-05T00:00:00"}